These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 24925260

  • 1. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
    Labrie F.
    J Steroid Biochem Mol Biol; 2015 Jan; 145():144-56. PubMed ID: 24925260
    [Abstract] [Full Text] [Related]

  • 2. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
    Grist E, de Bono JS, Attard G.
    J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
    [Abstract] [Full Text] [Related]

  • 3. The importance of targeting intracrinology in prostate cancer management.
    Hamid ARAH, Tendi W, Sesari SS, Mochtar CA, Umbas R, Verhaegh G, Schalken JA.
    World J Urol; 2019 May; 37(5):751-757. PubMed ID: 30350016
    [Abstract] [Full Text] [Related]

  • 4. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
    Lim AC, Attard G.
    Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
    [Abstract] [Full Text] [Related]

  • 5. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer.
    Labrie F.
    Endocr Relat Cancer; 2014 Aug; 21(4):R301-17. PubMed ID: 24825748
    [Abstract] [Full Text] [Related]

  • 6. Hormonal therapy of prostate cancer.
    Labrie F.
    Prog Brain Res; 2010 Aug; 182():321-41. PubMed ID: 20541672
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
    Penning TM.
    J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
    [Abstract] [Full Text] [Related]

  • 8. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
    Pham S, Deb S, Ming DS, Adomat H, Hosseini-Beheshti E, Zoubeidi A, Gleave M, Guns ES.
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
    [Abstract] [Full Text] [Related]

  • 9. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.
    Urologia; 2010 Oct; 77(2):71-83. PubMed ID: 20890863
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 11. Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.
    Knuuttila M, Mehmood A, Huhtaniemi R, Yatkin E, Häkkinen MR, Oksala R, Laajala TD, Ryberg H, Handelsman DJ, Aittokallio T, Auriola S, Ohlsson C, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M.
    Am J Pathol; 2018 Jan; 188(1):216-228. PubMed ID: 29126837
    [Abstract] [Full Text] [Related]

  • 12. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
    Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV.
    Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
    [Abstract] [Full Text] [Related]

  • 13. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M, Huang Y, Ratnam M.
    Biochem Biophys Res Commun; 2016 Jul 22; 476(2):69-74. PubMed ID: 27179779
    [Abstract] [Full Text] [Related]

  • 14. Reconsideration of progression to CRPC during androgen deprivation therapy.
    Mizokami A, Namiki M.
    J Steroid Biochem Mol Biol; 2015 Jan 22; 145():164-71. PubMed ID: 24717975
    [Abstract] [Full Text] [Related]

  • 15. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
    Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzo LS, Evans CP, Li PK, Gao AC.
    Clin Cancer Res; 2020 Nov 15; 26(22):6064-6074. PubMed ID: 32928794
    [Abstract] [Full Text] [Related]

  • 16. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
    Courtney KD, Taplin ME.
    Curr Opin Oncol; 2012 May 15; 24(3):272-7. PubMed ID: 22327837
    [Abstract] [Full Text] [Related]

  • 17. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U.
    Prostate; 2019 Aug 15; 79(11):1211-1220. PubMed ID: 31251826
    [Abstract] [Full Text] [Related]

  • 18. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F.
    Bull Cancer; 2006 Sep 15; 93(9):949-58. PubMed ID: 16980238
    [Abstract] [Full Text] [Related]

  • 19. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 20. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
    Jentzmik F, Azoitei A, Zengerling F, Damjanoski I, Cronauer MV.
    World J Urol; 2016 Mar 22; 34(3):297-303. PubMed ID: 26100946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.